Eligibility criteria
Condition
Acute Myeloid Leukemia
Sex
Females and Males
Age
18 + years
Inclusion criteria
Show details
- Morphologic diagnosis of AML from bone marrow aspirate and biopsy
- Flow cytometry, performed at the study site, must demonstrate that the patient has AML
that is CD33+, based on local laboratory criteria
- Age 18 years or older for relapsed or refractory patients for Phase I of this study
Exclusion criteria
Show details
- Patients with de novo AML of the M3 subtype
- AML following an antecedent hematologic disorder (myelodysplasia or
myeloproliferation) of > 2 months duration
- AML secondary to exposure to chemotherapy or radiation